

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of

Application Number

08/243,342

Filed

5/16/94

Art Unit

Examiner

Paper No. _____

Assistant Commissioner for Patents
Washington, DC 20231

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:

United States Patent Application Publication No. _____, page _____, line _____,

United States Patent Number 6,030,615, column Face, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Michael D. Linton
Signature

3/8/02
Date

Michael D. Linton
Typed or printed name

FOR PTO USE ONLY

Approved by: _____

(initials)

Unit: _____

RECEIVED
FOR CENTER 1600/2900
02 MAR 12 AM 9:16



US006030615A

United States Patent

[19]

[11] **Patent Number:****6,030,615****Bucala et al.**[45] **Date of Patent:****Feb. 29, 2000****[54] COMBINATION METHOD FOR TREATING DISEASES CAUSED BY CYTOKINE-MEDIATED TOXICITY**

[75] **Inventors:** Richard J. Bucala; Robert A. Mitchell; Jurgen Bernhagen; Thierry F. Calandra, all of New York; Anthony Cerami, Shelter Island, all of N.Y.

[73] **Assignee:** The Picower Institute for Medical Research, Manhasset, N.Y.

[21] **Appl. No.:** 08/471,546

[22] **Filed:** Jun. 6, 1995

Related U.S. Application Data

[60] Division of application No. 08/462,350, Jun. 5, 1995, which is a continuation-in-part of application No. 08/243,342, May 16, 1994, which is a continuation-in-part of application No. 08/063,399, May 17, 1993, abandoned.

[51] **Int. Cl.⁷** A61K 39/395; A61K 38/19; C07K 14/52; C07K 16/00

[52] **U.S. Cl.** 424/145.1; 424/154.1; 424/156.1; 424/158.1; 424/172.1; 424/85.2; 530/387.1; 530/388.1; 530/388.23; 530/388.24; 530/388.75; 530/389.2; 530/351

[58] **Field of Search** 424/145.1, 154.1, 424/156.1, 158.1, 172.1, 85.2; 530/387.1, 388.1, 388.23, 388.24, 388.75, 389.2, 351

[56] References Cited**U.S. PATENT DOCUMENTS**

4,683,202 7/1987 Mullis .
4,708,937 11/1987 Remold 435/188
5,411,882 5/1995 Odink et al. 435/240.2

OTHER PUBLICATIONS

Natanson et al. *Ann. Int. Med.* 120(9):771-783, 1994.
Zuckerman et al. *Eur. J. Immunol.* 19:301-305, 1989.
The Physician's Desk Reference, 1990. ed. Publ. by Edward R. Barnhart; pp. 1341-1342.
David et al., "Delayed Hypersensitivity in Vitro: Its Mediation By Cell Free Substances Formed By Lymphoid Cell-Antigen Interaction", *Pathology* 56:72-77 (1966).
Bennett and Bloom, "Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity", *Science* 153:80-82 (1966).
Nathan et al., "Alterations of Macrophage by Mediators From Lymphocytes", *J. Exp. Medicine* 133:1356-1376 (1971).
Nathan et al., "Characterization of a Lymphocyte Factor Which Alters Macrophage Functions", *J. Exp. Medicine* 137:275-288 (1973).
Kohler and Milstein, "Continuous Culture of Fused Cells Secreting Antibody of Predefined Specificity" *Nature* 256:495-497 (1975).
Weiser et al., "Studies of Human Migration Inhibitory Factor: Characterization of Three Molecular Species", *J. Immunol.* 126:1958-1962 (1981).

Kaiser and Kezdy, "Secondary Structures of Proteins and Peptides in Amphiphilic Environments (A Review)", *Proc. Natl. Acad. Sci. USA* 80:1137-1143 (1983).

Peck, "The ELISA Method for Quantitation of Macrophage Migration from Agarose Microdroplets", *Immunol. Methods* 64:179-187 (1983).

Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains", *Proc. Natl. Acad. Sci.* 81:6851-6855 (1984).

Sprung et al., "The Effects of High Dose Corticosteroids in Patients with Septic Shock", *New Eng. J. Med.* 311:1137-1143 (1984).

Beutler et al., "Purification of Catechin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-Induced Raw 264.7 Cells", *J. Exp. Med.* 161:984-995 (1985).

Erne et al., "Preferred Confirmation, Orientation, and Accumulation of Dynorphin A-(1-13)-Tridecapeptides on the Surfaces of Neutral Lipid Membranes", *Biochemistry* 24:4263-4265 (1985).

Beutler et al., "Catechin/Tumor Necrosis Factor: Production, Distribution, and Metabolic Fate in Vivo", *J. Immunol.* 135:3972-3977 (1985).

Suzuki et al., "Pituitary-Dependent and Independent Secretion of CS Caused by Bacterial Endotoxin in Rats", *Am. J. Physiol.* 250:E470-E474 (1986).

Liu and Todd, "A Monoclonal Antibody Specific for a Monocyte-Macrophage Membrane Component Blocks the Human Monocyte Response to Migration Inhibitory Factor", *J. Immunol.* 137:448-455 (1986).

Thomas and Cappechi, "Site-Directed Mutagen by Gene Targeting in Mouse Embryo-Derived Stem Cells", *Cell* 51:503-512 (1987).

Bone et al., "A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic Shock", *New Eng. J. Med.* 311:1137-1141 (1987).

Ding et al., "Release of Reactive Nitrogen Intermediates and Reactive Oxygen Intermediates From Mouse Peritoneal Macrophages", *J. Immunol.* 141:2407-2413.

Smith, "Interleukin 2: Inception, Impact, and Implications", *Science* 240:1169-1176 (1988).

Michie et al., "Detection of Circulating Tumor Factor After Endotoxin Administration", *New Eng. J. Med.* 318:1481-1486 (1988).

(List continued on next page.)

Primary Examiner—Paula K. Hutzell
Assistant Examiner—Geetha P. Bansal
Attorney, Agent, or Firm—Davis Wright Tremaine

[57]

ABSTRACT

There is disclosed a method for treating an individual having a disease caused by cytokine-mediated toxicity comprising administering to the individual an effective amount of (a) an antibody that binds to an MIF polypeptide, wherein the MIF polypeptide has a molecular weight of about 12.5 kDa in combination with (b) anti-TNF α , anti-IL1, anti-IFN- γ , IL-1RA, a steroid, a glucocorticoid, or IL-10.

3 Claims, 22 Drawing Sheets